

Leucemia Linfática Crônica

CVP

Ciclofosfamida: 400 mg/m² VO D1 ao D5 (ou 800 mg/m² IV D1)

Vincristina: 1,4 mg/m² IV D1 (dose máxima 2 mg)

Prednisona: 100 mg/m² VO D1 ao D5

a cada 21 dias

Ref. (1)

FC

Ciclofosfamida: 1000 mg/m² IV D1

Fludarabina: 20 mg/m² IV D1 ao D5

a cada 21 ou 28 dias

Ref. (2)

Clorambucil

Clorambucil: 6 a 14 mg/dia VO como terapia de indução e então

0,7 mg/kg VO por 2 a 4 dias

a cada 21 dias

Ref. (3)

Fludarabina

Fludarabina: 20 a 30 mg/m² IV D1 ao D5

a cada 28 dias

Ref. (4)

FP

Fludarabina: 30 mg/m² IV D1 ao D5

Prednisona: 30 mg/m² IV D1 ao D5

a cada 28 dias

Ref. (5)

CP

Clorambucil: 30 mg/m² VO D1

Prednisona: 80 mg VO D1 ao D5

a cada 28 dias

Ref. (6)

FR

Fludarabina: 30 mg/m² IV D1 ao D5
Rituximabe: 375 mg/m² IV D1, D3 e D5
a cada 28 dias

Ref. (7)

FCR

Ciclo 1:

Fludarabina: 25 mg/m² IV D2-D4
Ciclofosfamida: 250 mg/m² IV D2-D4
Rituximabe: 375 mg/m² D1

Ciclo 2-6:

Fludarabina: 25 mg/m² IV D1-D3
Ciclofosfamida: 250 mg/m² IV D1-D3
Rituximabe: 500 mg/m² D1
a cada 28 dias

Ref. (8)

FCR-Lite

Ciclo 1:

Rituximabe: 375 mg/m² IV D1
Rituximabe: 500 mg/m² IV D14
Fludarabina: 20 mg/m² IV D2 ao D4
Ciclofosfamida: 150 mg/m² IV D2 ao D4

Ciclos 2-6:

Rituximabe: 500 mg/m² IV D1 e no D14
Fludarabina: 20 mg/m² IV em 30 minutos D1 ao D3
Ciclofosfamida: 150 mg/m² IV em 60 minutos D1 ao D3

Manutenção:

Rituximabe 500 mg/m² IV a cada 3 meses até recidiva
Ref. (9)

Alentuzumabe

Alentuzumabe: 3,10 e 30 mg IV em 2 horas D1, D2 e D3 respectivamente.

Alentuzumabe: 30 mg IV três vezes por semana até o total de 12 semanas (incluindo a semana com escalonamento) Ref. (10)

Rituximabe e Alentuzumabe

Ciclo 1:

Rituximabe: 375 mg/m² IV no D1 e 500 mg/m² IV D8, D15 e D22

Alentuzumabe: 30 mg/dia IV em infusão contínua D2 ao D7

Alentuzumabe: 30 mg/dia SC D10, D12, D17, D19, D24 e D26

Ciclo 2-3 (opcional):

Rituximabe: 500 mg/m² IV D1, D8, D15 e D22

Alentuzumabe: 30 mg/dia SC D3, D5, D10, D12, D17, D19, D24 e D26 Ref. (11)

Bendamustina e Rituximabe

Ciclo 1:

Bendamustina: 70 mg/m² IV D1 e D2

Rituximabe: 375 mg/m² IV D1

Ciclos 2-6:

Bendamustina: 70 mg/m² IV D1 e D2

Rituximabe: 500 mg/m² IV D1 Ref. (12)

Rituximabe e Corticóide em Dose Alta

Ciclos 1-3:

Solumedrol: 1000 mg/m² IV em 90 minutos uma vez ao dia D1 ao D5

Rituximabe: 375 mg/m² IV semanalmente por 4 semanas

Ref. (13)

OFAR

Ciclos 1-6:

Oxaliplatina: 25 mg/m² IV D1 ao D4

Fludarabina: 30 mg/m² IV D2 e D3

Citarabina: 1000 mg/m² IV D2 e D3

Rituximabe: 375 mg/m² IV D3 (Ciclo 1) e D1 (Ciclos 2-6)
Ref. (14)

CFAR

Ciclo 1:

Ciclofosfamida: 250 mg/m² IV D3 ao D5

Fludarabina: 25 mg/m² IV D3 ao D5

Alentuzumabe: 30 mg IV D1, D3 e D5

Rituximabe: 375 mg/m² IV D2 (ciclo 1) e 500mg/m² IV D2

(ciclo 2-6) Ref. (15)

1. Raphael B, *et al.* Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. *J clin Oncol* 1991;9:770-776.
2. Keating MJ, *et al.* Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. *Blood* 1998;92:1165-1171.
3. Dighiero G, *et al.* Chlorambucil in indolent chronic lymphocytic leukemia French cooperative Group on chronic Lymphocytic leukemia. *N Engl J Med* 1998;338:1506-1514.
4. Keating MJ, *et al.* Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. *Blood* 1988;92:1165-1171.
5. O'Brien S, *et al.* Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. *Blood* 1993;82:1695-1700.
6. Raphael B, *et al.* Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. *J clin Oncol* 1991;9:770-776.
7. Byrd JC, *et al.* Randomized phase 2 study of fludarabine with

concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B9712. *Blood* 2003;101:6-14.

8. Keating M, *et al.* Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for CLL. *J Clin Oncol* 2005;22:4079-4088.
9. Fonn KA, *et al.* Chemoimmunotherapy with low dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol* 2009; 27:498-503.
10. Hillmen P, *et al.* Alemtuzumab compared with chlorambucil as first line therapy for chronic lymphocytic leukemia. *J Clin Oncol* 2007;25:5616-5623.
11. Faderl S, *et al.* Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. *Cancer* 2010; 116:2360-2365.
12. Firsten K, *et al.* Bendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: a multicenter phase II Trial of the German CLL Study Group. *Blood* 2008; 112:Abstract 330.
13. Castro JE, *et al.* Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. *Leukemia* 2008; 22:2048-53.
14. Tsimberidou AM, *et al.* Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 2008; 26:196-203.
15. Badoux XC, *et al.* Chemoimmunotherapy with Cyclophosphamide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). *Blood* 2009; 114:Abstract 3431.